Fig. 2 | Scientific Reports

Fig. 2

From: Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study

Fig. 2

Survival analysis for patients according to the International Metastatic RCC Database Consortium (IMDC) risk classification. (A) Objective response rates stratified by the number of IMDC risk factors. (B) Progression-free survival (PFS) by IMDC risk group: favorable- (n = 27), intermediate- (n = 60), and poor-risk (n = 31) groups. (C) Overall survival (OS) by IMDC risk group. (D) Comparative analysis of baseline C-reactive protein levels between IMDC poor- and favorable/intermediate risk-groups.

Back to article page